Letter: ICRF 159.
D000818:Animals; D000963:Antimetabolites / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D004357:Drug Synergism; D005472:Fluorouracil / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D009362:Neoplasm Metastasis / Q000517:prevention & control; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011407:Propane / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use
D000963:Antimetabolites; D010879:Piperazines; D004317:Doxorubicin; D003520:Cyclophosphamide; D011407:Propane; D005472:Fluorouracil